Friday, November 30, 2018

Caffeinated Coffee, The Liver Protective and Anti Non Alcoholic Liver Disease Beverage

Habitual caffeinated coffee intake may have a potential of curing Non-Alcoholic Liver Disease, some scientists found.

Non-alcohol fatty liver disease (NAFLD) is a chronic medical condition of the fatty liver caused by excessive fat deposited (steatosis) in the liver other than over-consumption of alcohol.

The disease is a common liver disorder found in most developed countries, probably due to over-consumption of carbohydrates which are considered as a major stimulus for hepatic de novo lipogenesis (DNL), the esterification of plasma free fatty acids, such as American diet.



According to a clinical assessment conducted by the joint study led by the Global Clinical Research, " Hepatic de novo lipogenesis(DNL), the synthesis of new fatty acids from non-lipid sources, is thought to play a pivotal role in the development of NAFLD"(4).

In compared to lipids that were defined as soluble substances in organic solvents, including the various types of fatty acids, eicosanoids, fatty alcohols, fatty aldehydes, ...... and hydrocarbons, fatty acids from non-lipid sources are men make substances that do not rely on organic solvents, but use other chemicals to separate the lipids from the rest of the food, including buttermilk fat, beef fat (tallow, suet), chicken fa,t cream pork fat, (lard),... and stick margarine



Dr. Paglialunga S. the lead author suggested as of today, there is no NAFLD-specific therapeutic agent available. However, pharmaceutical drugs aimed at reducing hepatic fat accretion may prove to be a powerful ally in the treatment and management of this disease(4).

Some researchers also said a chronic metabolic derangement referred to steatosis are directly associated with patients with obesity and type 2 diabetes(4).

According to the statistic, approximately, 80 millions of US adults suffer from Non-alcoholic fatty liver disease (NAFLD) in which 30% to 40% of those patients show no visible signs and symptoms.

However, most patients with Non-Alcoholic Liver Disease may experience signs and symptoms of abdominal swelling, enlarged blood vessels just beneath the skin's surface, spleen, red palms,.... and jaundice as a result of liver advanced scarring (steatohepatitis and cirrhosis).



If you have some of the above symptoms, please see your doctor right the way to rule out the possibility.

Coffee, second to green tea, is a popular and social beverage all over the world, particularly in the West, made from roasted bean from the Coffea plant, native to tropical Africa and Madagascar.


According to a retrospective cross-sectional study on patients with non-alcoholic fatty liver disease (NAFLD), hepatitis C virus (HCV), and hepatitis B virus (HBV) infection to determine the effects of coffee intake on a non-invasive marker of liver fibrosis, coffee intake of 2 or more cups per day demonstrated a significant reduced liver symptom of stiffness, after adjustment for age, gender, smoking, alcohol consumption, in compared to other subgroups.

Additionally, in the review of epidemiological and clinical evidence by the Zhejiang University, researchers suggested coffee intake may have a profoundly reduced severity and risk of non-alcoholic fatty liver disease (NAFLD) prevalence.

In fact, the effect of coffee on attenuated risk of non-alcoholic fatty liver disease (NAFLD) incidence may be also involved other chemical constituents other than caffeine.

Dr. Chen S, the lead researchers suggested that said, "Several possible mechanisms underlying coffee's hepatoprotective effects in NAFLD include antioxidative, anti-inflammatory, and antifibrotic effects".


Interestingly, the review of literature published in the database of Medline and Embase up to March 2015, showed that coffee and coffee caffeine intake have a strong impact in protecting the liver against complications of fibrosis incidence.

Information collected indicated that coffee and coffee caffeine intake have an enormous demonstration in ameliorated risk and symptoms of Nonalcoholic liver disease, but some researchers suggested that other components may also play an important role in the enhancement of these results.


Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight

How To Get Rid Of Eye Floaters
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

Back to Kyle J. Norton Homepage http://kylejnorton.blogspot.ca


Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)

Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bioscience, ISSN 0975-6299.

Sources
(1) Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B by Hodge A1,2, Lim S3, Goh E4, Wong O5, Marsh P6, Knight V7, Sievert W8,9, de Courten B10.(PubMed)
(2) Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? by Chen S1, Teoh NC, Chitturi S, Farrell GC.(PubMed)
(3) Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies by Marventano S1, Salomone F2, Godos J3, Pluchinotta F4, Del Rio D5, Mistretta A1, Grosso G6.(PubMed)
(4) Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease by Sabina Paglialunga1 and Clayton A. Dehn(PubMed)

No comments:

Post a Comment